nach oben

Journal of Gastrointestinal Cancer

Erschienen in:

29.08.2020 | Case Report

Ampullary Adenocarcinoma: a Mini-Review and a Case Report of a Clinically Stable Disease Patient Treated with Herbal Supplements

verfasst von: Khin Maung Lwin, Ye Htut Linn, Yamin Kyaw Swar Dee

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Excerpt

The ampulla of Vater is situated where the common bile duct (CBD) merges with the pancreatic duct and exits into the duodenum. The portion is lined by the columnar epithelium which is similar to that of the lower CBD. Ampullary carcinoma (AC) is a rare malignant tumour originating from the ampulla of Vater and it accounts for approximately 0.2% of all gastrointestinal tract malignancies [1]. Among the 2564 periampullary adenocarcinoma patients who had undergone pancreaticoduodenectomy (PD), AC is the second commonest (accounting for about 11–16%), preceded by carcinoma of the head of the pancreas (HOP)/duct which takes about 66% [2, 3]. According to the data from the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program, there were 5625 cases of AC between 1973 and 2005, and this has been increasing since 1973 [4]. In Burgundy, France, age-standardized incidence rates were 0.46 and 0.30 per 100,000 inhabitants for men and women respectively based on the 34-year data. The incidence rate increased from 0.26 (1976–1984) to 0.58 (2003–2009) for men and remained stable for women [5]. Metabolic diseases such as diabetes, gall stone, chronic pancreatitis, high total cholesterol, low high-density lipoprotein, and low apolipoprotein A were found to be significantly related to ampullary cancer [6]. …

Allard-Picou A. Ampullary carcinoma: practice essentials, Background, Pathophysiology. 2019. https://emedicine.medscape.com/article/276413-overview. Accessed 21 July 2020.

He J, Ahuja N, Makary MA, Cameron JL, Eckhauser FE, Choti MA, et al. 2564 resected periampullary adenocarcinomas at a single institution: trends over three decades. HPB. 2014;16(1):83–90. https://doi.org/10.1111/hpb.12078.CrossRefPubMed

Yeo CJ, Cameron JL, Sohn TA, Lillemoe KD, Pitt HA, Talamini MA, et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg. 1997;226(3):248–60. https://doi.org/10.1097/00000658-199709000-00004.CrossRefPubMedPubMedCentral

Albores-Saavedra J, Schwartz AM, Batich K, Henson DE. Cancers of the ampulla of Vater: demographics, morphology, and survival based on 5,625 cases from the SEER program: cancer of the ampulla of Vater. J Surg Oncol. 2009;100(7):598–605. https://doi.org/10.1002/jso.21374.CrossRefPubMed

Rostain F. Trends in incidence and management of cancer of the ampulla of Vater. World J Gastroenterol. 2014;20(29):10144. https://doi.org/10.3748/wjg.v20.i29.10144.CrossRefPubMedPubMedCentral

He X-D, Wu Q, Liu W, Hong T, Li JJ, Miao RY, et al. Association of metabolic syndromes and risk factors with ampullary tumors development: a case-control study in China. World J Gastroenterol. 2014;20(28):9541–8. https://doi.org/10.3748/wjg.v20.i28.9541.CrossRefPubMedPubMedCentral

Ray-Offor E. Periampullary cancer and cancer in head of pancreas: what is the difference? Gastroenterol Hepatol Endosc. 2019;4(3):1–3. https://doi.org/10.15761/GHE.1000184.CrossRef

Mccarthy MJ, Evans J, Sagar G, Neoptolemos JP. Prediction of resectability of pancreatic malignancy by computed tomography. Br J Surg. 1998;85(3):320–5. https://doi.org/10.1046/j.1365-2168.1998.00584.x.CrossRefPubMed

Pancreatic Section of the British Society of Gastroenterology, Pancreatic Society of Great Britain and Ireland, Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland, Royal College of Pathologists, Special Interest Group for Gastro-I. Guidelines for the management of patients with pancreatic cancer periampullary and ampullary carcinomas. Gut. 2005;54(suppl_5):v1–16. https://doi.org/10.1136/gut.2004.057059.CrossRef

10.

Hornick JR, Johnston FM, Simon PO, Younkin M, Chamberlin M, Mitchem JB, et al. A single-institution review of 157 patients presenting with benign and malignant tumors of the ampulla of Vater: management and outcomes. Surg. 2011;150(2):169–76. https://doi.org/10.1016/j.surg.2011.05.012.CrossRef

11.

Klein F, Jacob D, Bahra M, et al. Prognostic factors for long-term survival in patients with ampullary carcinoma: the results of a 15-year observation period after pancreaticoduodenectomy. HPB Surg. 2014;2014:970234. https://doi.org/10.1155/2014/970234.CrossRefPubMedPubMedCentral

12.

Kawamata H, Yamashita K, Nakamura K, Katagiri H, Ishii K, Takahashi Y, et al. Perineural invasion and preoperative serum CA19-9 as predictors of survival in biliary tract cancer. Anticancer Res. 2013;33:583–94.PubMed

13.

Lee HS, Jang JS, Lee S, Yeon MH, Kim KB, Park JG, et al. Diagnostic accuracy of the initial endoscopy for ampullary tumors. Clin Endosc. 2015;48(3):239–46. https://doi.org/10.5946/ce.2015.48.3.239.CrossRefPubMedPubMedCentral

14.

Patel V, Jowell P, Obando J, Guy C, Burbridge R. Does ampullary adenoma size predict invasion on EUS? Does invasion on EUS predict presence of malignancy? Endosc Int Open. 2016;04(12):E1313–8. https://doi.org/10.1055/s-0042-121001.CrossRef

15.

Manta R. Linear endoscopic ultrasonography vs magnetic resonance imaging in ampullary tumors. World J Gastroenterol. 2010;16(44):5592–7. https://doi.org/10.3748/wjg.v16.i44.5592.CrossRefPubMedPubMedCentral

16.

Ridtitid W, Schmidt SE, Al-Haddad MA, LeBlanc J, DeWitt JM, McHenry L, et al. Performance characteristics of EUS for locoregional evaluation of ampullary lesions. Gastrointest Endosc. 2015;81(2):380–8. https://doi.org/10.1016/j.gie.2014.08.005.CrossRefPubMed

17.

Buscail L, Pagès P, Berthélemy P, Fourtanier G, Frexinos J, Escourrou J. Role of EUS in the management of pancreatic and ampullary carcinoma: a prospective study assessing resectability and prognosis. Gastrointest Endosc. 1999;50(1):34–40. https://doi.org/10.1016/s0016-5107(99)70341-x.CrossRefPubMed

18.

Dacha S, Chawla S, Lee JE, Keilin SA, Cai Q, Willingham FF. Endoscopic retrograde cholangiopancreatography with ampullary biopsy vs ERCP alone: a matched-pairs controlled evaluation of outcomes and complications. Gastroenterol Rep (Oxf). 2017;5(4):277–81. https://doi.org/10.1093/gastro/gow044.CrossRef

19.

Agoff SN, Crispin DA, Bronner MP, Dail DH, Hawes SE, Haggitt RC. Neoplasms of the ampulla of Vater with concurrent pancreatic intraductal neoplasia: a histological and molecular study. Mod Pathol. 2001;14(3):139–46. https://doi.org/10.1038/modpathol.3880270.CrossRefPubMed

20.

Zimmermann C, Wolk S, Aust DE, Meier F, Saeger H-D, Ehehalt F, et al. The pathohistological subtype strongly predicts survival in patients with ampullary carcinoma. Sci Rep. 2019;9(1):12676. https://doi.org/10.1038/s41598-019-49179-w.CrossRefPubMedPubMedCentral

21.

Kondo S, Takada T, Miyazaki M, Miyakawa S, Tsukada K, Nagino M, et al. Guidelines for the management of biliary tract and ampullary carcinomas: surgical treatment. J Hepatobiliary Pancreat Surg. 2008;15(1):41–54. https://doi.org/10.1007/s00534-007-1279-5.CrossRefPubMedPubMedCentral

22.

Gao Y, Zhu Y, Huang X, Wang H, Huang X, Yuan Z. Transduodenal ampullectomy provides a less invasive technique to cure early ampullary cancer. BMC Surg. 2016;16(1):36. https://doi.org/10.1186/s12893-016-0156-z.CrossRefPubMedPubMedCentral

23.

Tran TC. Ampullary tumors: endoscopic versus operative management. Surg Innov. 2004;11(4):255–63. https://doi.org/10.1177/155335060401100409.CrossRefPubMed

24.

Yoon Y-S, Kim S-W, Park SJ, Lee HS, Jang J-Y, Choi MG, et al. Clinicopathologic analysis of early ampullary cancers with a focus on the feasibility of ampullectomy. Ann Surg. 2005;242(1):92–100. https://doi.org/10.1097/01.sla.0000167853.04171.bb.CrossRefPubMedPubMedCentral

25.

Song J, Liu H, Li Z, Yang C, Sun Y, Wang C. Long-term prognosis of surgical treatment for early ampullary cancers and implications for local ampullectomy. BMC Surg. 2015;15(1):32. https://doi.org/10.1186/s12893-015-0019-z.CrossRefPubMedPubMedCentral

26.

Bhatia S, Miller RC, Haddock MG, Donohue JH, Krishnan S. Adjuvant therapy for ampullary carcinomas: the Mayo Clinic experience. Int J Radiat Oncol Biol Phys. 2006;66(2):514–9. https://doi.org/10.1016/j.ijrobp.2006.04.018.CrossRefPubMed

27.

Sikora SS, Balachandran P, Dimri K, Rastogi N, Kumar A, Saxena R, et al. Adjuvant chemo-radiotherapy in ampullary cancers. Eur J Surg Oncol. 2005;31(2):158–63. https://doi.org/10.1016/j.ejso.2004.08.013.CrossRefPubMed

28.

Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Ann Surg. 1999;230(6):776–82. https://doi.org/10.1097/00000658-199912000-00006.CrossRefPubMedPubMedCentral

29.

Willett CG, Warshaw AL, Convery K, Compton CC. Patterns of failure after pancreaticoduodenectomy for ampullary carcinoma. Surg Gynecol Obstet. 1993;176(1):33–8.PubMed

30.

Zhou J, Hsu CC, Winter JM, Pawlik TM, Laheru D, Hughes MA, et al. Adjuvant chemoradiation versus surgery alone for adenocarcinoma of the ampulla of Vater. Radiother Oncol. 2009;92(2):244–8. https://doi.org/10.1016/j.radonc.2009.05.006.CrossRefPubMedPubMedCentral

31.

Ecker BL, Vollmer CM, Behrman SW, Allegrini V, Aversa J, Ball CG, et al. Role of adjuvant multimodality therapy after curative-intent resection of ampullary carcinoma. JAMA Surg. 2019;154(8):706–14. https://doi.org/10.1001/jamasurg.2019.1170.CrossRefPubMedPubMedCentral

32.

Nassour I, Hynan LS, Christie A, Minter RM, Yopp AC, Choti MA, et al. Association of adjuvant therapy with improved survival in ampullary cancer: a national cohort study. J Gastrointest Surg. 2018;22(4):695–702. https://doi.org/10.1007/s11605-017-3624-6.CrossRefPubMed

33.

Morak MJM, van der Gaast A, Incrocci L, van Dekken H, Hermans JJ, Jeekel J, et al. Adjuvant intra-arterial chemotherapy and radiotherapy versus surgery alone in resectable pancreatic and periampullary cancer: a prospective randomized controlled trial. Ann Surg. 2008;248(6):1031–41. https://doi.org/10.1097/sla.0b013e318190c53e.CrossRefPubMed

34.

Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract, Takada T, Amano H, Yasuda H, Nimura Y, Matsushiro T, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma?: a phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer. 2002;95(8):1685–95. https://doi.org/10.1002/cncr.10831.CrossRef

35.

Barton RM, Copeland EM. Carcinoma of the ampulla of Vater. Surg Gynecol Obstet. 1983;156(3):297–301.PubMed

36.

Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, et al. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA. 2012;308(2):147–56. https://doi.org/10.1001/jama.2012.7352.CrossRefPubMed

37.

Chan C, Quintanilla-Martinez L, Richaud-Patin Y, Llorente L, Robles-Diaz G, Campuzano M. Clinical behavior and prognostic factors of periampullary adenocarcinoma. Ann Surg. 1995;222(5):632–7. https://doi.org/10.1097/00000658-199511000-00005.CrossRefPubMedPubMedCentral

38.

Jiang Z-Q, Varadhachary G, Wang X, Kopetz S, Lee JE, Wang H, et al. A retrospective study of ampullary adenocarcinomas: overall survival and responsiveness to fluoropyrimidine-based chemotherapy. Ann Oncol. 2013;24(9):2349–53. https://doi.org/10.1093/annonc/mdt191.CrossRefPubMedPubMedCentral

39.

Cen P, Wray CJ, Zhang S, Thosani NC, Dinh BC, Gonzalez A, et al. Durable response for ampullary and duodenal adenocarcinoma with a nab-paclitaxel plus gemcitabine ± cisplatin combination. Cancer Med. 2019;8(7):3464–70. https://doi.org/10.1002/cam4.2181.CrossRefPubMedPubMedCentral

40.

Saito H, Takada T, Miyazaki M, Miyakawa S, Tsukada K, Nagino M, et al. Radiation therapy and photodynamic therapy for biliary tract and ampullary carcinomas. J Hepatobiliary Pancreat Surg. 2008;15(1):63–8. https://doi.org/10.1007/s00534-007-1281-y.CrossRefPubMedPubMedCentral

41.

Park HM, Park S-J, Han S-S, Hong SK, Hong EK, Kim S-W. Very early recurrence following pancreaticoduodenectomy in patients with ampullary cancer. Med. 2019;98(44):e17711. https://doi.org/10.1097/md.0000000000017711.CrossRef

42.

Hatzaras I, George N, Muscarella P, Melvin WS, Ellison EC, Bloomston M. Predictors of survival in periampullary cancers following pancreaticoduodenectomy. Ann Surg Oncol. 2010;17(4):991–7. https://doi.org/10.1245/s10434-009-0883-9.CrossRefPubMedPubMedCentral

43.

Chang DK, Jamieson NB, Johns AL, Scarlett CJ, Pajic M, Chou A, et al. Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of Vater. J Clin Oncol. 2013;31(10):1348–56. https://doi.org/10.1200/jco.2012.46.8868.CrossRefPubMed

44.

Choi W, An S, Kwon E, Eo W, Lee S. Impact of standardized allergen-removed Rhus verniciflua Stokes extract on advanced adenocarcinoma of the ampulla of Vater: a case series. Evid Based Complement Altern Med. 2013;2013:1–8. https://doi.org/10.1155/2019/6497691.CrossRef

45.

Werthmann PG, Kempenich R, Lang-Avérous G, Kienle GS. Long-term survival of a patient with advanced pancreatic cancer under adjunct treatment with Viscum album extracts: a case report. World J Gastroenterol. 2019;25(12):1524–30. https://doi.org/10.3748/wjg.v25.i12.1524.CrossRefPubMedPubMedCentral

46.

Kiran TGS, Kolakota RK. Role of chamomile in cancer treatment. J Pathol Clin Med Res. 2018;1:001.

47.

Shankar E, Goel A, Gupta K, Gupta S. Plant flavone apigenin: an emerging anticancer agent. Curr Pharmacol Rep. 2017;3(6):423–46. https://doi.org/10.1007/s40495-017-0113-2.CrossRefPubMedPubMedCentral

48.

Hoensch H, Groh B, Edler L, Kirch W. Prospective cohort comparison of flavonoid treatment in patients with resected colorectal cancer to prevent recurrence. World J Gastroenterol. 2008;14(14):2187. https://doi.org/10.3748/wjg.14.2187.CrossRefPubMedPubMedCentral

49.

Amin ARMR, Karpowicz PA, Carey TE, Arbiser J, Nahta R, Chen ZG, et al. Evasion of anti-growth signaling: a key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds. Semin Cancer Biol. 2015;35:S55–77. https://doi.org/10.1016/j.semcancer.2015.02.005.CrossRefPubMed

50.

Arora S, Singh S, Piazza GA, Contreras CM, Panyam J, Singh AP. Honokiol: a novel natural agent for cancer prevention and therapy. Curr Mol Med. 2012;12(10):1244–52. https://doi.org/10.2174/156652412803833508.CrossRefPubMedPubMedCentral

51.

Arora S, Bhardwaj A, Srivastava SK, Singh S, McClellan S, Wang B, et al. Honokiol arrests cell cycle, induces apoptosis, and potentiates the cytotoxic effect of gemcitabine in human pancreatic cancer cells. Chandra D, editor. PLoS ONE. 2011;6(6):e21573. https://doi.org/10.1371/journal.pone.0021573.CrossRefPubMedPubMedCentral

52.

Songjang W, Jiraviriyakul A. Honokiol and magnolol inhibit growth, metastasis and induce apoptosis in human cholangiocarcinoma. Biomed Pharmacol J. 2019;12(2):759–73. https://doi.org/10.13005/bpj/1698.CrossRef

53.

Golkar L, Ding X-Z, Ujiki MB, Salabat MR, Kelly DL, Scholtens D, et al. Resveratrol inhibits pancreatic cancer cell proliferation through transcriptional induction of macrophage inhibitory cytokine-1. J Surg Res. 2007;138(2):163–9. https://doi.org/10.1016/j.jss.2006.05.037.CrossRefPubMed

54.

Ko J-H, Sethi G, Um J-Y, Shanmugam MK, Arfuso F, Kumar AP, et al. The role of resveratrol in cancer therapy. Int J Mol Sci. 2017;18(12):2589. https://doi.org/10.3390/ijms18122589.CrossRefPubMedCentral

55.

Liu P, Liang H, Xia Q, Li P, Kong H, Lei P, et al. Resveratrol induces apoptosis of pancreatic cancers cells by inhibiting miR-21 regulation of BCL-2 expression. Clin Transl Oncol. 2013;15(9):741–6. https://doi.org/10.1007/s12094-012-0999-4.CrossRefPubMed

56.

Lwin KM, Lwin MKT. Vitis species. Yangon: FAME Publishing House; 2012.

57.

Line-Edwige M, Guy Raymond F, François E, Edouard N. Antiproliferative effect of alcoholic extracts of some Gabonese medicinal plants on human colonic cancer cells. Afr J Trad Compl Alt Med. 2010;6(2):112–7.CrossRef

58.

Gore RD. Wheatgrass: green blood can help to fight cancer. J Clin Diagn Res. 2017;11(6):ZC40–2. https://doi.org/10.7860/JCDR/2017/26316.10057.CrossRefPubMedPubMedCentral

59.

Food and Agriculture Organization of the United Nations, World Health Organization (2006) Probiotics in food: health and nutritional properties and guidelines for evaluation. Food and Agriculture Organization of the United Nations: World Health Organization, Rome.

60.

Vivarelli S, Salemi R, Candido S, Falzone L, Santagati M, Stefani S, et al. Gut microbiota and cancer: from pathogenesis to therapy. Cancers. 2019;11(1):38. https://doi.org/10.3390/cancers11010038.CrossRefPubMedCentral

61.

Nemunaitis J, Cunningham C, Senzer N, Kuhn J, Cramm J, Litz C, et al. Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients. Cancer Gene Ther. 2003;10(10):737–44. https://doi.org/10.1038/sj.cgt.7700634.CrossRefPubMed

62.

Toso JF, Gill VJ, Hwu P, Marincola FM, Restifo NP, Schwartzentruber DJ, et al. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol. 2002;20(1):142–52. https://doi.org/10.1200/jco.2002.20.1.142.CrossRefPubMed

Titel: Ampullary Adenocarcinoma: a Mini-Review and a Case Report of a Clinically Stable Disease Patient Treated with Herbal Supplements
verfasst von: Khin Maung Lwin
Ye Htut Linn
Yamin Kyaw Swar Dee
Publikationsdatum: 29.08.2020
Verlag: Springer US
Erschienen in: Journal of Gastrointestinal Cancer / Ausgabe 2/2021
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI: https://doi.org/10.1007/s12029-020-00501-0

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Ampullary Adenocarcinoma: a Mini-Review and a Case Report of a Clinically Stable Disease Patient Treated with Herbal Supplements

Excerpt

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2021

ABO Blood Group and the Risk of Esophageal Squamous Cell Carcinoma in Kashmir, a High Risk Region

Perceived Threats toward Esophageal Cancer among Immediate Relatives of Sufferers: a Qualitative Study

Association Between the hOGG1 1245C>G (rs1052133) Polymorphism and Susceptibility to Colorectal Cancer: a Meta-analysis Based on 7010 Cases and 10,674 Controls

Rare, Unusual Causality of Acute Appendicitis

The Investigation of 14 Appendiceal Mucocele Cases Encountered in 4850 Appendectomy Patients

Retrospective epidemiological study on stomach cancer in a region of western Algeria: about 394 cases between 2011 and 2015

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie